HSC-based humanized mouse model of pulmonary fibrosis achieves stable multilineage human immune engraftment without graft-versus-host disease Nintedanib treatment confirms clinically consistent drug response, validating the model for evaluation of human-specific biologics and cell therapies International patent filed under the Patent Cooperation Treaty in February 2026, with national phase entries

ten23 health today highlights its research collaboration with dsm-firmenich, focused on expanding excipient options for parenteral biologic drug products. By combining complementary expertise, the collaboration aims to address one of the longstanding challenges in biologic formulation development: the limited availability of excipients suitable for injectable medicines.

A new peer-reviewed study in JCI Insight by DTU and Cytosurge reveals dermokine’s critical role in wound healing and skin cancer. To decode these mechanisms, researchers used Cytosurge’s CellEDIT service to successfully engineer notoriously fragile human keratinocytes. By bypassing the toxicity of traditional bulk transfection, CellEDIT’s vector-free, direct-to-nucleus CRISPR delivery genera

If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacks NDA includes positive data from successful clinical program demonstrating rapid relief and sustained response to resolution of HAE attack symptoms and a well-tolerated safety profile PDUFA action date set for April 23, 2027

Five sites recruiting in US study of DLL3-targeting 212Pb-labelled Radio-DARPin MP0712 Dosing ongoing in first patients, consecutively moving to subsequent dosing cycles Initial data anticipated within the coming months, comprehensive efficacy data expected in 2027